biotech · Hypertrophic Cardiomyopathy · Arrhythmogenic Right Ventricular Cardiomyopathy · TNYA
Tenaya Therapeutics
Tenaya Therapeutics is a biotech organization headquartered in South San Francisco, USA. It trades on NYSE under ticker TNYA. Primary therapeutic focus areas include Hypertrophic Cardiomyopathy, Arrhythmogenic Right Vent
South San Francisco, USA HQ
2016 Founded
99 Employees
Public company Type
TNYA · NYSE Ticker
Company details
- Status
- Public
- HQ
- South San Francisco, USA
- Founded
- 2016
- Employees
- 99
- Programs
- 2
- Drugs
- 1
- Patents
- 13
TN-401
Phase 1 · gene therapy · Arrhythmogenic Right Ventricular Cardiomyopathy
TN-401 for Arrhythmogenic Right Ventricular Cardiomyopathy is a Phase 1 program (gene_therapy) at Tenaya Therapeutics with 1 ClinicalTrials.gov record(s).
Internal code TN-401-0012
Full intelligence profile for this program is being prepared.
At a glance
- Sponsor
- Tenaya Therapeutics
- Phase
- Phase 1
- Modality
- gene_therapy
- Indication
- Arrhythmogenic Right Ventricular Cardiomyopathy
- Status
- active
- Trials
- 1